ResMed Inc. (NYSE: RMD) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 21.58 | EPS (ttm) | 10.34 | Insider Own | 0.95% | Shs Outstand | 145.06M | Perf Week | 6.79% |
| Market Cap | 32.37B | Forward P/E | 16.83 | EPS next Y | 13.26 | Insider Trans | -2.76% | Shs Float | 144.16M | Perf Month | 2.17% |
| Enterprise Value | 31.52B | PEG | 2.11 | EPS next Q | - | Inst Own | - | Short Float | 9.39% | Perf Quarter | 6.55% |
| Income | 1.52B | P/S | 5.84 | EPS this Y | 16.62% | Inst Trans | - | Short Ratio | 8.74 | Perf Half Y | -12.40% |
| Sales | 5.54B | P/B | 4.99 | EPS next Y | 9.97% | ROA | 17.30% | Short Interest | 13.54M | Perf YTD | -7.36% |
| Book/sh | 44.76 | P/C | 19.49 | EPS next 5Y | 10.23% | ROE | 24.41% | 52W High | 293.80 -24.05% | Perf Year | -20.08% |
| Cash/sh | 11.45 | P/FCF | 17.51 | EPS past 3/5Y | 21.52% 17.37% | ROIC | 19.63% | 52W Low | 180.27 23.78% | Perf 3Y | -0.01% |
| Dividend Est. | 2.40 (1.08%) | EV/EBITDA | 14.43 | Sales past 3/5Y | 12.88% 11.72% | Gross Margin | 61.69% | Volatility | 3.38% 2.91% | Perf 5Y | -15.55% |
| Dividend TTM | 2.40 (1.08%) | EV/Sales | 5.69 | EPS Y/Y TTM | 49.42% | Oper. Margin | 34.28% | ATR (14) | 6.99 | Perf 10Y | 240.62% |
| Dividend Ex-Date | May 14, 2026 | Quick Ratio | 2.33 | Sales Y/Y TTM | 18.21% | Profit Margin | 27.44% | RSI (14) | 65.85 | Recom | 2.74 |
| Dividend Gr. 3/5Y | 9.53% 7.70% | Current Ratio | 3.01 | EPS Q/Q | 17.70% | SMA20 | 9.69% | Beta | 0.75 | Target Price | 242.22 |
| Payout | 22.39% | Debt/Eq | 0.14 | Sales Q/Q | 10.76% | SMA50 | 11.79% | Rel Volume | 1.16 | Prev Close | 215.19 |
| Employees | 10,600 | LT Debt/Eq | 0.14 | Earnings | Aug 06 | SMA200 | -3.61% | Avg Volume | 1.49M | Price | 223.14 |
| IPO Date | Jun 02, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.32% 0.81% | Net Debt/EBITDA | -0.37 | Volume | 1,725,513 | Change | 3.69% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-21-26 | Reiterated | UBS | Buy | $345 → $300 |
| Jul-16-26 | Reiterated | RBC Capital | Outperform | $276 → $234 |
| Jul-15-26 | Reiterated | Mizuho | Outperform | $265 → $220 |
| Jul-13-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jul-10-26 | Reiterated | Jefferies | Hold | $240 → $225 |
| Jul-08-26 | Reiterated | RBC Capital | Outperform | $314 → $276 |
| Jul-08-26 | Reiterated | Wells Fargo | Equal Weight | $280 → $225 |
| Jun-22-26 | Reiterated | Keybanc | Overweight | $290 → $266 |
| Jun-17-26 | Downgrade | Morgan Stanley | Overweight → Equal Weight | $305 → $230 |
| May-01-26 | Reiterated | Robert W. Baird | $254 → $225 |
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | FY 2018 6/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,538 | 5,146 | 4,685 | 4,223 | 3,578 | 3,197 | 2,957 | 2,607 | 2,340 | |
| Cost of Goods Sold Incl. D&A | 2,121 | 2,091 | 2,030 | 1,867 | 1,554 | 1,358 | 1,239 | 1,070 | 978 | |
| Gross Profit | 3,417 | 3,055 | 2,655 | 2,356 | 2,024 | 1,839 | 1,718 | 1,537 | 1,362 | |
| Selling, General and Administrative Excl. Other | 1,082 | 991 | 917 | 874 | 739 | 670 | 677 | 645 | 600 | |
| Research and Development | 358 | 331 | 308 | 288 | 254 | 225 | 202 | 181 | 155 | |
| Other Operating Expense | 78 | 48 | 110 | 62 | 31 | 40 | 30 | 131 | 65 | |
| Operating Income | 1,900 | 1,685 | 1,320 | 1,132 | 1,000 | 904 | 810 | 579 | 542 | |
| Interest Expense | 29 | 13 | 46 | 47 | 22 | 24 | 40 | 36 | 28 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 35 | 5 | -9 | 17 | -17 | 4 | -36 | -24 | 8 | |
| Net Income Before Taxes | 1,903 | 1,678 | 1,265 | 1,102 | 960 | 884 | 733 | 519 | 521 | |
| Income Taxes | 384 | 277 | 244 | 204 | 181 | 409 | 111 | 114 | 206 | |
| Consolidated Net Income | 1,521 | 1,401 | 1,021 | 898 | 779 | 475 | 622 | 405 | 316 | |
| Net Income From Continuing Operations | 1,521 | 1,401 | 1,021 | 898 | 779 | 475 | 622 | 405 | 316 | |
| Net Income | 1,521 | 1,401 | 1,021 | 898 | 779 | 475 | 622 | 405 | 316 | |
| EPS (Recurring) | 10.38 | 9.55 | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | |
| EPS (Basic, Before Extraordinaries) | 10.38 | 9.55 | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | |
| EPS (Diluted) | 10.34 | 9.51 | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | |
| EBITDA | 2,185 | 1,913 | 1,534 | 1,359 | 1,177 | 1,104 | 990 | 706 | 680 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 21.58 | 27.13 | 27.66 | 35.88 | 39.55 | 76.09 | 44.96 | 43.58 | 47.30 | |
| Price To Sales Ratio | 5.88 | 7.37 | 6.01 | 7.61 | 8.55 | 11.18 | 9.35 | 6.69 | 6.33 | |
| Gross Margin | 61.70 | 59.37 | 56.67 | 55.79 | 56.57 | 57.52 | 58.10 | 58.96 | 58.21 | |
| Operating Margin | 34.31 | 32.74 | 28.18 | 26.81 | 27.95 | 28.28 | 27.39 | 22.21 | 23.16 | |
| Net Margin | 27.46 | 27.23 | 21.79 | 21.26 | 21.77 | 14.86 | 21.03 | 15.54 | 13.50 | |
| Shares Outstanding | 146 | 147 | 147 | 147 | 146 | 145 | 144 | 143 | 143 | |
| Market Capitalization | 32,578 | 37,926 | 28,139 | 32,120 | 30,606 | 35,745 | 27,648 | 17,450 | 14,812 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO | Jul 07 '26 | Option Exercise | 146.34 | 4,991 | 730,383 | 471,214 | Jul 09 |
| Farrell Michael J. | Chairman and CEO | Jul 07 '26 | Sale | 218.55 | 4,991 | 1,090,771 | 466,223 | Jul 09 |
| Farrell Michael J. | Chairman and CEO | Jun 08 '26 | Option Exercise | 146.34 | 4,991 | 730,383 | 471,214 | Jun 09 |
| Farrell Michael J. | Chairman and CEO | Jun 08 '26 | Sale | 193.96 | 4,991 | 968,064 | 466,256 | Jun 09 |
| Farrell Michael J. | Chairman and CEO | May 07 '26 | Option Exercise | 146.34 | 4,991 | 730,383 | 471,214 | May 11 |
| Farrell Michael J. | Chairman and CEO | May 07 '26 | Sale | 207.82 | 4,991 | 1,037,233 | 466,223 | May 11 |
| Farrell Michael J. | Chairman and CEO | Apr 07 '26 | Option Exercise | 146.34 | 4,991 | 730,383 | 471,214 | Apr 09 |
| Farrell Michael J. | Chairman and CEO | Apr 07 '26 | Sale | 225.50 | 4,991 | 1,125,486 | 466,223 | Apr 09 |
| Sandercock Brett | Chief Financial Officer | Apr 01 '26 | Sale | 224.31 | 1,000 | 224,310 | 83,495 | Apr 03 |
| FARRELL PETER C | Director | Apr 01 '26 | Sale | 225.00 | 2,000 | 450,000 | 60,773 | Apr 02 |
| Farrell Michael J. | Chairman and CEO | Mar 09 '26 | Option Exercise | 146.34 | 4,991 | 730,383 | 471,214 | Mar 11 |
| Farrell Michael J. | Chairman and CEO | Mar 09 '26 | Sale | 251.03 | 4,991 | 1,252,902 | 466,223 | Mar 11 |
| FARRELL PETER C | Director | Mar 04 '26 | Sale | 260.22 | 2,000 | 520,440 | 62,773 | Mar 05 |
| Sandercock Brett | Chief Financial Officer | Mar 02 '26 | Sale | 254.30 | 1,000 | 254,300 | 84,495 | Mar 03 |
| Farrell Michael J. | Chairman and CEO | Feb 09 '26 | Option Exercise | 146.34 | 4,991 | 730,383 | 471,214 | Feb 10 |